MetaCap

Cullinan Therapeutics Inc. Company Profile

NASDAQ: CGEMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

8.89-0.18 (-1.98%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Cullinan Therapeutics at a glance

Cullinan Therapeutics Inc. (NASDAQ: CGEM) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Cambridge, MA. Cullinan Therapeutics is led by Mr. Nadim Ahmed M.S. and employs about 109 people. The company's shares have traded publicly since 2021.

At a market capitalization of $588.8 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001789972, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Cullinan Therapeutics do?

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Business description based on the company's public filings.

Company information

Legal name
Cullinan Therapeutics Inc.
Ticker
NASDAQ: CGEM
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Nadim Ahmed M.S.
Employees
109
Headquarters
One Main Street, Cambridge, MA, United States
Phone
617 410 4650
IPO year
2021
Market cap
$588.83M
SEC CIK
0001789972
Latest annual report
10-K · Mar 10, 2026

Companies similar to Cullinan Therapeutics

CGEM peer companies
CompanyPrice% ChgMarket capCompare
SRZNSurrozen Inc.28.46-7.21%$596.40Mvs CGEM
FDMT4D Molecular Therapeutics Inc.10.23-4.57%$576.76Mvs CGEM
ENTXEntera Bio Ltd.3.31+0.76%$575.53Mvs CGEM
DBVTDBV Technologies S.A. ADR9.02-4.25%$566.82Mvs CGEM
IAMIambic Therapeutics Inc.13.11-8.06%$621.42Mvs CGEM
ETRAElectra Therapeutics Inc.8.11-9.28%$509.85Mvs CGEM
VALNValneva SE ADR5.16-3.82%$490.86Mvs CGEM
ATTOAttovia Therapeutics Inc.15.10-3.08%$690.26Mvs CGEM

Related